Sanofi

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

News

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business, according to Bloomberg.

News

EU first to approve Dupixent for COPD

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.

News

Verona’s first-in-class COPD drug ‘could transform market’

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.

News

Sanofi: NICE would reject Sarclisa even if it cost nothing

Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consid

News

Sobi gets EU okay for long-acting haemophilia A drug

The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any

MSD stakes claim to RSV prevention market for infants

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

EU first to approve Dupixent for COPD

Verona’s first-in-class COPD drug ‘could transform market’

Sanofi: NICE would reject Sarclisa even if it cost nothing

Sobi gets EU okay for long-acting haemophilia A drug

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks